Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets
Transmission of highly pathogenic avian H5N1 viruses from poultry to humans have raised fears of an impending influenza pandemic. Concerted efforts are underway to prepare effective vaccines and therapies including polyclonal or monoclonal antibodies against H5N1. Current efforts are hampered by the...
Saved in:
Published in | PLoS medicine Vol. 6; no. 4; p. e1000049 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
21.04.2009
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Transmission of highly pathogenic avian H5N1 viruses from poultry to humans have raised fears of an impending influenza pandemic. Concerted efforts are underway to prepare effective vaccines and therapies including polyclonal or monoclonal antibodies against H5N1. Current efforts are hampered by the paucity of information on protective immune responses against avian influenza. Characterizing the B cell responses in convalescent individuals could help in the design of future vaccines and therapeutics.
To address this need, we generated whole-genome-fragment phage display libraries (GFPDL) expressing fragments of 15-350 amino acids covering all the proteins of A/Vietnam/1203/2004 (H5N1). These GFPDL were used to analyze neutralizing human monoclonal antibodies and sera of five individuals who had recovered from H5N1 infection. This approach led to the mapping of two broadly neutralizing human monoclonal antibodies with conformation-dependent epitopes. In H5N1 convalescent sera, we have identified several potentially protective H5N1-specific human antibody epitopes in H5 HA[(-10)-223], neuraminidase catalytic site, and M2 ectodomain. In addition, for the first time to our knowledge in humans, we identified strong reactivity against PB1-F2, a putative virulence factor, following H5N1 infection. Importantly, novel epitopes were identified, which were recognized by H5N1-convalescent sera but did not react with sera from control individuals (H5N1 naïve, H1N1 or H3N2 seropositive).
This is the first study, to our knowledge, describing the complete antibody repertoire following H5N1 infection. Collectively, these data will contribute to rational vaccine design and new H5N1-specific serodiagnostic surveillance tools. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ICMJE criteria for authorship read and met: SK ALS YR CPS AL FS JM LRK KS HG. Agree with the manuscript’s results and conclusions: SK ALS YR CPS AL FS JM LRK KS HG. Designed the experiments/the study: SK CPS KS HG. Analyzed the data: SK ALS YR CPS HG. Collected data/did experiments for the study: SK ALS YR JM LRK. Wrote the first draft of the paper: SK HG. Contributed to the writing of the paper: SK ALS CPS AL KS HG. Conducted virus neutralization assays involving H5N1 wild-type virus and performed preliminary work on evaluating the efficiency of synthetic peptides to block the neutralizing activity of H5 HA-specific hMAbs: ALS. Provided reagents: AL. Supervised the work done at IRB and provided human monoclonal antibodies: FS. Performed the microneutralization assay and analyzed the data from the assays: JM LRK. Designed some of the experiments: KS. |
ISSN: | 1549-1676 1549-1277 1549-1676 |
DOI: | 10.1371/journal.pmed.1000049 |